---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-020031"
form_type: "8-K"
ticker: "BFRI"
cik: "0001858685"
company_name: "Biofrontera Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:37:14.343463+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Biofrontera Q1 revenue down 9% to $7.9M; net loss $10.4M; Ameluz license renegotiated

## Summary
- Q1 revenue $7.9M, down 9% YoY from $8.7M due to Change Healthcare data breach reimbursement issues.
- Net loss $10.4M ($2.88 per share) vs $7.5M ($5.60 per share) in prior year; loss per share improved due to share count increase.
- Cash $3.8M at quarter end vs $1.3M at Dec 31, 2023; raised $8M via preferred placement plus $8M via warrant exercises.
- Renegotiated Ameluz transfer price to 25% for 2024-2025 (down from 40-50%) and will assume US clinical trial management from June 1.
- FDA accepted sNDA for Ameluz dosage from 1 to 3 tubes; final decision expected by Oct 4, 2024; new RhodoLED XL lamp sales expected Q2 2024.

## SEC filing metadata
- accession: 0001493152-24-020031
- form_type: 8-K
- ticker: BFRI
- cik: 0001858685
- company_name: Biofrontera Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858685/000149315224020031/0001493152-24-020031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858685/000149315224020031/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-020031
- JSON: https://secwatch.observer/filing/0001493152-24-020031.json
- Plain text: https://secwatch.observer/filing/0001493152-24-020031.txt

## Key facts
- Earnings Releases
  Biofrontera Inc. reported the three months ended March 31, 2024 results: revenue $7.9 million, net income $10.4 million, or $(2.88) per share, EPS $(2.88) per share.
  - Period: the three months ended March 31, 2024
  - Revenue: $7.9 million
  - Net income: $10.4 million, or $(2.88) per share
  - EPS: $(2.88) per share
  - Result: reported results
  source text: 2024 and provided a business update. Highlights from the first quarter of 2024 and subsequent weeks included the following: ● Total revenues for the first quarter of 2024 were $7.9 million, a 9% decrease from the same period of the prior year primarily driven by reimbursement headwinds our customers experienced due to the Change Healthcare data breach ● Cash and
  evidence_url: https://www.sec.gov/Archives/edgar/data/1858685/000149315224020031/0001493152-24-020031-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.